标题
Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2023-06-24
DOI
10.1200/jco.23.00258
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
- (2022) D. Gale et al. ANNALS OF ONCOLOGY
- When immunotherapy meets surgery in non-small cell lung cancer
- (2022) Roy S. Herbst et al. CANCER CELL
- Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer
- (2022) James Isaacs et al. DRUGS
- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
- (2022) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer
- (2022) Jia-Tao Zhang et al. Cancer Discovery
- Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
- (2022) Mariano Provencio et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
- (2022) Jeanne Tie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer
- (2022) Siwei Wang et al. Journal of Hematology & Oncology
- Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
- (2022) Mary O’Brien et al. LANCET ONCOLOGY
- P03.03 MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery
- (2021) S. Peters et al. Journal of Thoracic Oncology
- 93TiP MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy
- (2021) D.R. Spigel et al. Journal of Thoracic Oncology
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- (2021) Enriqueta Felip et al. LANCET
- Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA
- (2021) David M. Kurtz et al. NATURE BIOTECHNOLOGY
- 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
- (2021) C. Zhou et al. ANNALS OF ONCOLOGY
- Perioperative ctDNA-Based Molecular Residual Disease Detection for Non–Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)
- (2021) Liang Xia et al. CLINICAL CANCER RESEARCH
- Early assessment of circulating tumor DNA after curative‐intent resection predicts tumor recurrence in early‐stage and locally advanced non‐small‐cell lung cancer
- (2021) Silvia Waldeck et al. Molecular Oncology
- Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
- (2021) Bin Qiu et al. Nature Communications
- Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
- (2021) Everett J. Moding et al. Cancer Discovery
- Integrating genomic features for non-invasive early lung cancer detection
- (2020) Jacob J. Chabon et al. NATURE
- Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring
- (2020) Asaf Zviran et al. NATURE MEDICINE
- Liquid biopsy for early stage lung cancer moves ever closer
- (2020) Christian Rolfo et al. Nature Reviews Clinical Oncology
- Perioperative dynamic changes in circulating tumor DNA in lung cancer patients (DYNAMIC)
- (2019) Kezhong Chen et al. CLINICAL CANCER RESEARCH
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- (2017) Christopher Abbosh et al. NATURE
- Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
- (2017) Aadel A. Chaudhuri et al. Cancer Discovery
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
- (2014) Aaron M Newman et al. NATURE MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now